Richard Greenberg

Dr. Richard Greenberg is a Professor of Internal Medicine with a focus on Infectious Diseases at the University of Kentucky. His career spans over three decades, with expertise in vaccine development, HIV/AIDS research, and clinical trials for antifungal therapies. He holds academic appointments in the School of Medicine and collaborates with institutions like the National Institutes of Health (NIH) and pharmaceutical companies on vaccine trials for diseases such as hepatitis, HIV, pneumococcal pneumonia, and smallpox. His research emphasizes translational medicine, particularly in vaccine efficacy, immune response characterization, and antifungal drug efficacy in immunocompromised patients. Dr. Greenberg has led numerous clinical trials for novel vaccines (e.g., oral cholera, pandemic influenza) and contributed to pivotal studies on zoster (shingles) vaccine safety and pneumococcal conjugate vaccines in elderly populations. His work bridges academia and industry, addressing global health challenges through rigorous clinical research.

Education:

• Medical Degree: Tufts University School of Medicine
• Residency: Indiana University Medical Center and Louisiana State University Medical School
• Fellowship: Louisiana State University Medical Center
• NIH Training Fellowship: University of Virginia Medical Center

Research Interests: Dr. Greenberg’s research centers on:

• Vaccine development for infectious diseases (e.g., HIV, influenza, smallpox)
• Immunocompromised patient care, particularly in histoplasmosis and cryptococcosis
• Antifungal therapy optimization (e.g., isavuconazonium for mucormycosis)
• HIV-associated complications and antiretroviral drug effects
• Clinical trials for novel drug delivery systems like MucoJet oral vaccines

Grants & Collaborations: His work has been funded by NIH (NIAID), industry partnerships (e.g., Bavarian Nordic, GSK), and DoD for defense-related vaccines (e.g., botulism, plague). He serves as a sub-investigator for NIH-funded VTEU trials and leads vaccine efficacy studies at the University of Kentucky’s clinical research unit.

Labs & Teams: Collaborates with the university’s infectious disease research group and biostatistics core, focusing on clinical trial design and biomarker analysis for vaccine responses.